Delivra Corp (fka DLRVF)

[Wo]

Delivra Publishes Positive Results Utilizing its Unique Platform Technology for Topical Doxycycline

https://finance.yahoo.com/news/delivra-publishes-positive-results-utilizing-120000645.html?.tsrc=applewf

CNW Group
February 6, 2019, 7:00 AM EST
TORONTO , Feb. 6, 2019 /CNW/ - Delivra Corp. (TSXV: DVA - "Delivra" or the "Company") today announced the publication of positive data from a laboratory and clinical study demonstrating the stability, safety and efficacy to treat diabetic wounds, using Delivra's platform technology, to deliver a topical version of the prescription drug, doxycycline. These results were published in the respected peer-reviewed scientific journal, Wounds Research. This article may be found at the following link: https://www.ncbi.nlm.nih.gov/pubmed/30664497.

A large number of diabetics will develop diabetic leg wounds, which could cause amputation and other complications, which could ultimately result in death. With the aging populations in Canada , USA and Europe , diabetes is becoming a significant problem and is a highly unmet need in medicine today. Delivra continues its significant work in the diabetic field to address this important and growing need.

"This impressive data further validates Delivra's novel technology and offers doctors and their patients an effective, safe and convenient cream for diabetic wounds, without the side effects of oral doxycycline. With a robust pharmaceutical pipeline of high-value innovative products, Delivra-doxycycline formulation provides a unique and growing commercialization opportunity. As such, we will continue to pursue out-licensing opportunities for major global markets to unlock the value of our unique portfolio," said Dr. Joseph Gabriele , CEO of Delivra.

Delivra has filed a provisional patent to protect its unique formulation using doxycycline. DelivraTM topical doxycycline is currently available by prescription across Canada through the compound pharmacy services of NKS Health Ltd.